The Hidden Cost of Switching Pharmaceutical Intermediate Suppliers: A Buyer’s Calculator
Switching intermediate suppliers for 20% lower price? Six hidden costs including bridging studies, regulatory filings, and method revalidation can reach $600K.
blog
ICH Q2 Analytical Method Validation: What Your Intermediate COA Doesn’t Tell You
This guide decodes the seven validation parameters defined in ICH Q2(R2) from an intermediate buyer’s perspective, explains why stability-indicating methods matter for retest dating, and provides six questions buyers should ask suppliers about their analytical methods.
ICH Q11 Starting Material Selection: A Practical Guide for Pharmaceutical Intermediate Buyers
Learn how ICH Q11 starting material rules affect pharmaceutical intermediate sourcing—supplier boundaries, COA red flags, and a practical buyer’s checklist.
Polymorphism in Pharmaceutical Intermediates: Why Solid Form Control Matters
This guide explains what polymorphism means for intermediate buyers, how ICH Q6A Decision Tree #4 governs solid form control, which COA red flags signal polymorph gaps, and three questions every buyer should ask their supplier before committing to a purchase.
Elemental Impurities (ICH Q3D) in Pharmaceutical Intermediates: A Buyer’s Guide
This guide explains the four element classes, the 30% control threshold that determines whether routine testing is required, the difference between ICP-MS and ICP-OES analytical methods, and five red flags on supplier COAs that signal inadequate elemental impurity control.
Chiral Purity and Enantiomeric Excess (ee%) in Pharmaceutical Intermediates
This guide explains what ee% measures, why it differs from optical purity, how chiral HPLC validates stereochemical integrity, and which COA fields separate genuine process control from cosmetic data.
Empagliflozin Intermediate Sourcing: Buyers Guide
This buyer’s guide maps the Boehringer Ingelheim synthesis route, identifies four commercially critical intermediates with CAS numbers, explains why six chiral centers create six separate quality checkpoints.
Pharmaceutical Intermediate Storage Conditions: What Buyers Must Know
This guide explains three degradation pathways triggered by improper storage (hydrolysis, photodegradation, and thermal decomposition), decodes what “Store at CRT” actually means under USP <659> and ICH Q1A(R2), and gives procurement teams a practical checklist.
Nitrosamine Impurity Risk in Intermediates: Guide
This guide explains three formation pathways (amine + nitrite reaction, recovered solvent contamination, and shared-equipment cross-contamination), walks through the CPCA classification framework for assessing risk levels, and provides five questions every procurement team should ask their intermediate supplier — plus four red flags to spot on a COA.
Intermediate Retest Date vs Expiry Date: What Buyers Must Know
This guide clarifies the three terms (retest date, expiry date, shelf life) with ICH definitions, explains how manufacturers assign retest periods using a risk-based stability framework, and gives you five questions to ask any supplier — plus four red flags to watch for on COA date labels.